Regeneron says its COVID-19 antibody treatment cut medical visits in trial


Corrects trial size

Oct 28 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O said on Wednesday that its COVID-19 antibody cocktail - the experimental treatment that U.S. President Donald Trump received - significantly reduced medical visits in a trial of around 800 patients with mild-to-moderate sickness.

The company said it has shared the results with the U.S. Food and Drug Administration as part of its review of the company's request for emergency use authorization of the treatment.

(Reporting by Michael Erman; Editing by Leslie Adler)

((; +1 646-223-6021; Reuters Messaging:

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.